2023年12月13日,备受瞩目的《肿瘤学年鉴》(Annals of Oncology,影响因子:50.5)期刊在线发布了2023版ESMO早期乳腺癌临床实践指南——“Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up”。本期(...
1.ESMO Metastatic Breast Cancer Living Guideline; V1.1; May 2023. 2.Hurvitz SA, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023 Jan ...
1. ESMO Metastatic Breast Cancer Living Guideline; V1.1; May 2023. 2. Hurvitz SA, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023 Ja...
国外指南中,2023NCCN乳腺癌指南(v4)已将 SG 作为晚期 TNBC 的二线治疗全人群的 1 类优选推荐[8];《ESMO Metastatic Breast Cancer Living Guideline》(ESMO-MCBS,2023 v1.1)则推荐 SG 作为晚期 TNBC 二线首选治疗方案,且置于 T-DXd 之前[9];另外,2023ESMO HER2 低表达共识也声明对于 HER2 低表达晚期 TNBC ...
在2023年12月13日,备受瞩目的《肿瘤学年鉴》(Annals of Oncology,影响因子:50.5)期刊在线发布了2023版ESMO早期乳腺癌临床实践指南——“Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up”。本期【肿瘤资讯】整理了筛查、诊断及局部区域治疗的要点及推荐意见,供读者参阅...
ASCO乳腺癌指南强推荐SG用于接受过内分泌治疗及至少2种针对转移性疾病全身治疗的不可切除或转移性HR+/HER2-乳腺癌患者[13]。对于ET-CDK4/6抑制剂经治的HR+/HER2- mBC患者,《ESMO Metastatic Breast Cancer Living Guideline》(ESMO-MCBS,2023 v1.1)推荐HER2 0的患者优先使用SG进行治疗[14]。
ASCO乳腺癌指南强推荐SG用于接受过内分泌治疗及至少2种针对转移性疾病全身治疗的不可切除或转移性HR+/HER2-乳腺癌患者[13]。对于ET-CDK4/6抑制剂经治的HR+/HER2- mBC患者,《ESMO Metastatic Breast Cancer Living Guideline》(ESM...
2022 版 CACA-CBCS 指南推荐将 SG 作为晚期 TNBC 二线治疗的优选[6],同时 2023 版CSCOBC 指南再次推荐 SG 用于晚期 TNBC 二线全人群治疗[7]。国外指南中,2023NCCN乳腺癌指南(v4)已将 SG 作为晚期 TNBC 的二线治疗全人群的 1 类优选推荐[8];《ESMO Metastatic Breast Cancer Living Guideline》(ESMO-MCBS,...
1.ESMO Metastatic Breast Cancer Living Guideline; V1.1; May 2023. 2.Hurvitz SA, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023 Jan ...
国外指南中,2023NCCN乳腺癌指南(v4)已将 SG 作为晚期 TNBC 的二线治疗全人群的 1 类优选推荐[8];《ESMO Metastatic Breast Cancer Living Guideline》(ESMO-MCBS,2023 v1.1)则推荐 SG 作为晚期 TNBC 二线首选治疗方案,且置于 T-DXd 之前[9];另外,2023ESMO HER2 低表达共识也声明对于 HER2 低表达晚期 TNBC ...